We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Prevymis

News List

NICE recommends Prevymis on the NHS after re-evaluation europeanpharmaceuticalreview
June 05, 2019
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.
NICE recommendation for MSD’s Prevymis after re-evaluation pharmatimes
June 03, 2019
Document, recommending MSD’s Prevymis (letermovir) for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) within the NHS.
MSD’s antiviral Prevymis fails to win NICE backing pharmatimes
July 05, 2018
MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
After hep C hit, Merck's antiviral business nabs approval for CMV fighter Prevymis fiercepharma
November 10, 2017
Merck & Co.'s antiviral business suffered some serious blows this year, but it now boasts a brand-new drug: Prevymis, a cytomegalovirus fighter now FDA-approved to prevent infection in adults undergoing stem cell transplants.